deltatrials
Recruiting PHASE2 INTERVENTIONAL 6-arm NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR)

Sponsor: Eikon Therapeutics

Conditions Bladder Cancer Melanoma Non Small Cell Lung Cancer Pancreatic Cancer Solid Tumor, Adult Triple Negative Breast Cancer Virus-associated Tumors
Interventions Association atezolizumab + BDB001 + RT Association atezolizumab + BDB001+ RT
Updated 15 times since 2019 Last updated: Oct 1, 2025 Started: Mar 31, 2021 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bladder Cancer and Melanoma and is currently actively recruiting participants. Eikon Therapeutics leads this study, which shows 15 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2019 – ~Oct 2020 · 17 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshot~Oct 2023 – ~Jun 2024 · 8 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 6 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. Oct 2023 — Jun 2024 [monthly]

    Recruiting PHASE2

  2. Apr 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  3. Sep 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  4. Mar 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  6. Jun 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Mar 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2

  8. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

  9. Oct 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  10. May 2019 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eikon Therapeutics
  • Institut Bergonié
  • National Cancer Institute, France
  • Roche Pharma AG
Data source: Institut Bergonié

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations